Gene · 1144
CHRND: cholinergic receptor nicotinic delta subunit
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CHRND: cholinergic receptor nicotinic delta subunit. Genes, record 1144. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1144
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q07001 | Acetylcholine receptor subunit delta | 517 | 13 | Ensembl, GeneID, HGNC |
Source UniProt
Patents38
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 41252 | Q07001 | Espacenet |
| EP 4670794 A2 | 2025-12-31 | 27 | Q07001 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 1682 | Q07001 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 2887 | Q07001 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 944 | Q07001 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 5873 | Q07001 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 5873 | Q07001 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 944 | Q07001 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 1682 | Q07001 | Espacenet |
| EP 4551941 A2 | 2025-05-14 | 49 | Q07001 | Espacenet |
1 to 10 of 38
See all 38 patentsDrugs28
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATRACURIUM | CHEMBL1360 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| ATRACURIUM BESYLATE | CHEMBL1200527 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| CISATRACURIUM | CHEMBL1201248 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| CISATRACURIUM BESYLATE | CHEMBL1200641 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| DECAMETHONIUM | CHEMBL1190 | Muscle-type nicotinic acetylcholine receptor partial agonist | PARTIAL AGONIST | ChEMBL |
| DECAMETHONIUM BROMIDE | CHEMBL1134 | Muscle-type nicotinic acetylcholine receptor partial agonist | PARTIAL AGONIST | ChEMBL |
| DOXACURIUM | CHEMBL1237123 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| DOXACURIUM CHLORIDE | CHEMBL1237099 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| GALLAMINE | CHEMBL360055 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
| GALLAMINE TRIETHIODIDE | CHEMBL1200993 | Muscle-type nicotinic acetylcholine receptor antagonist | ANTAGONIST | ChEMBL |
1 to 10 of 28
See all 28 drugsTrials47
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07271472 | ROCURONIUM | ClinicalTrials.gov | ||
| NCT07143799 | CISATRACURIUM | ClinicalTrials.gov | ||
| NCT07121699 | ROCURONIUM | ClinicalTrials.gov | ||
| NCT07035301 | ROCURONIUM | ClinicalTrials.gov | ||
| NCT07033442 | ROCURONIUM | ClinicalTrials.gov | ||
| NCT06714981 | ROCURONIUM BROMIDE | ClinicalTrials.gov | ||
| NCT06514209 | CISATRACURIUM | ClinicalTrials.gov | ||
| NCT06214169 | CISATRACURIUM | ClinicalTrials.gov | ||
| NCT06212492 | CISATRACURIUM | ClinicalTrials.gov | ||
| NCT06203405 | CISATRACURIUM | ClinicalTrials.gov |
1 to 10 of 47
See all 47 trialsNIH grants256
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CHRND papers | Newest fiscal year |
|---|---|---|---|
| F30DA059437 | Subcortical targets involved in the action of psilocybin in learned and innate escape behaviors | 2 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 2 | 2025 |
| P50AA012870 | Center for the Translational Neuroscience of Alcoholism | 2 | 2025 |
| DP1DA058737 | Deciphering the single-nucleus genomic regulatory structure of opioid use disorder in the human brain | 1 | 2025 |
| I01BX004820 | Genetic Vulnerability for Sustained Multi-Substance Use in MVP | 1 | 2025 |
| KL2TR001862 | Institutional Career Development Core | 1 | 2025 |
| P01HL141084 | Multiscale Systems to Elucidate Susceptibility and Cardioprotective Mechanisms in Cardio-oncology | 1 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 1 | 2025 |
| P30CA016056 | Roswell Park Cancer Center Support Grant | 1 | 2025 |
| P30CA023108 | Cancer Center Support Grant | 1 | 2025 |
1 to 10 of 256Source NIH's project files
See all 256 nih grantsPapers294
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Clinical Variability and Genotype-Driven Outcomes in CHRND-Related Congenital Myasthenic Syndrome. | Eur J Neurol | 2026 | 42657756 | PubTator, text mining | PubMed |
| Integrative network pharmacology, transcriptomics, and molecular docking identify candidate Centella asiatica constituents and targets in neurodegenerative diseases. | PLoS One | 2026 | 42536688 | PubTator, text mining | PubMed |
| Systematic reanalysis of next-generation sequencing data in 101 neuromuscular disorder families enhances diagnostic yield, reveals intronic variants, and identifies a novel disease gene. | J Neurol | 2026 | 42474733 | PubTator, text mining | PubMed |
| Suspected Adult-Onset Congenital Myasthenic Syndrome Associated With a Heterozygous CHRND Variant in a Patient With Seropositive Rheumatoid Arthritis: A Case Report. | Am J Case Rep | 2026 | 42324739 | PubTator, text mining | PubMed |
| Non-pterygium Escobar syndrome from compound-heterozygous CHRNG variants: genotype-phenotype insights. | Hum Genome Var | 2026 | 41826296 | PubTator, text mining | PubMed |
| Exploring molecular signatures in PURA syndrome using muscle proteomics and serum biomarkers. | J Neurol | 2026 | 41575592 | PubTator, text mining | PubMed |
| Whole-exome sequencing study of opioid dependence offers novel insights into the contributions of exome variants. | Transl Psychiatry | 2025 | 41052974 | PubTator, text mining | PubMed |
| Biallelic CRELD1 variants cause severe muscle weakness and infantile epilepsy. | Brain Commun | 2025 | 40980404 | PubTator, text mining | PubMed |
| Slow-Channel Congenital Myasthenic Syndrome Due to CHRND Mutation in South Korea. | J Clin Neurol | 2025 | 40878311 | PubTator, text mining | PubMed |
| Persistent Inflammation, Maladaptive Remodeling, and Fibrosis in the Kidney Following Long COVID-like MHV-1 Mouse Model. | Diseases | 2025 | 40863220 | PubTator, text mining | PubMed |
1 to 10 of 294
See all 294 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1144
GET https://conductscience.org/api/genes/v1/1144/patents?page=2